Immune Response Corporation (NASDAQ SC:IMNR)!!!!!!!! KURSZIEL 8-10 Dollar = 400% ???? - 500 Beiträge pro Seite

[js200]

Dawson James Securities Initiates Coverage On Immune Response Corp. (IMNR) With A Buy Rating And A 12-Month Price Target Of $8-$10

Thursday , September 04, 2003 14:11 ET

FORT LAUDERDALE, Fla., Sep 04, 2003 /PRNewswire via COMTEX/ -- Robert Wasserman, Director of Research for Dawson James Securities, a Division of ViewTrade Financial, has initiated coverage on Immune Response Corporation (Nasdaq: IMNR) with a buy rating and a 12-month price target of $8-$10.

Dawson James is a research-oriented healthcare/biotech boutique investment firm with offices in Florida and New Jersey. Dawson James focuses on delivering high quality independent research on firms in Florida and the Southeast to both retail and institutional investors.

IMNR, based in Carlsbad, CA, is a biopharmaceutical company developing a therapeutic vaccine for the treatment of human immunodeficiency virus (HIV) infection. Currently, IMNR is focusing its research and development efforts on REMUNE, an immune-based therapy for HIV infection which was been the subject of over 18 clinical studies and 2,000 patients over the past ten years.

Mr. Wasserman believes that Immune Response can gain additional share valuation in the near-term with the successful progress of REMUNE clinical trials in Europe and additional discussions with the US FDA. The $8-$10 price target for IMNR stock is based on the share price two years ago, before disappointing initial determinations were made by the Spanish data review board. Mr. Wasserman feels that new studies in Europe are progressing to overcome this initial reluctance and discussions are being held with the US FDA.

Robert Wasserman is responsible for research in the areas of specialty and generic pharmaceuticals, healthcare services and biotechnology. Mr. Wasserman has over fifteen years` experience in equity research specializing in all areas of health care. Among the areas covered are pharmaceuticals, medical devices, healthcare services and biotechnology. He has analyzed and written reports on over 100 publicly traded health care companies. This research report is available by contacting Mr. Wasserman at [phone], or by e- mail: [e-mail].

Information and statements contained herein, other than historical information, should be considered forward-looking, which involve risk and uncertainties. The securities referenced are speculative in nature and may not be suitable for your investment objective. Dawson James may have a long or short position in the securities; its officers, directors and affiliates may maintain positions in the securities referenced that may change at any time without notice.

For further information about Dawson James contact Robert D. Keyser Jr. at 954-928-0928 or email [e-mail] .

Dawson James Securities is a member of the National Association of Securities Dealers, CRD number 47116.

SOURCE Dawson James Securities


CONTACT: Robert D. Keyser Jr., Dawson James Securities, [phone]
or [e-mail]

URL: http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: Florida
New Jersey
California
INDUSTRY KEYWORD: FIN
HEA
MTC
BIO
SUBJECT CODE: RTG

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


09/04/2003 (11:51 ET) BTC: JMP Provides Fall Preview of Biotech Industry - Knobias



09/03/2003 (12:13 ET) VOLUME(+): IMNR Volume 23% > 20-adsv, Stock +13.50% - Knobias



08/29/2003 (09:12 ET) HCR: Jyske Banks Starts Healthcare Sector at Neutral - Knobias



08/28/2003 (03:06 ET) The Immune Response Corporation Issues Notice Regarding The Redemption of Its Class A Warrants - PR Newswire



08/28/2003 (00:54 ET) The Immune Response Corporation Issues Notice Regarding The Redemption of Its Class A Warrants - PR Newswire



08/26/2003 (16:17 ET) IMNRW: Short Interest UNCHG at 0 in Aug 2003 - Knobias



08/26/2003 (16:17 ET) IMNRZ: Short Interest UNCHG at 0 in Aug 2003 - Knobias



08/26/2003 (16:17 ET) IMNR: Short Interest UP 52.4% to 2.1M in Aug 2003 - Knobias



08/25/2003 (08:56 ET) ERN(-): IMNR/Q2 (46c) vs (91c); Misses Q Est; No Guidance - Knobias



08/21/2003 (16:30 ET) BTC: Baird Remains Bullish on Biotech Industry - Knobias



08/19/2003 (17:14 ET) New 10-Q just released for IMNR - Edgar



08/19/2003 (05:30 ET) The Immune Response Corporation Appoints Paul Volberding, M.D., Leading HIV/AIDS Expert, to Scientific Advisory Board - Business Wire



08/15/2003 (16:41 ET) New NT 10-Q just released for IMNR - Edgar



08/14/2003 (12:10 ET) VOLUME(+): IMNRW Volume 180% > 20-adsv, Stock +75.00% - Knobias



08/14/2003 (11:01 ET) VOLUME(+): IMNR Volume 12% > 20-adsv, Stock +11.25% - Knobias



08/13/2003 (16:23 ET) CLOSER(+): Last 90 Min, IMNR Jumps +8.84%; Vol +364% - Knobias



08/06/2003 (14:46 ET) New 424B3 just released for IMNR - Edgar

JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/imnr.htm

JS200

[js200]

09/04/2003 (14:36 ET) VOLUME(+): IMNR Volume 62% > 20-adsv, Stock +12.23% - Knobias
09/04/2003 (14:29 ET) RATING(1): Dawson James Initiates IMNR Rating @ Buy - Knobias
09/04/2003 (14:11 ET) Dawson James Securities Initiates Coverage On Immune Response Corp. (IMNR) With A Buy Rating And A 12-Month Price Target Of $8-$10 - PR Newswire
09/04/2003 (14:09 ET) Dawson James Securities Initiates Coverage On Immune Response Corp. (IMNR) With A Buy Rating And A 12-Month Price Target Of $8-$10 - PR Newswire
09/04/2003 (11:51 ET) BTC: JMP Provides Fall Preview of Biotech Industry - Knobias


JS200

[js200]

RATING(1): Dawson James Initiates IMNR Rating @ Buy

Thursday , September 04, 2003 14:29 ET

Issuer: Immune Response Corporation (NasdaqSC: IMNR)
Analyst Firm: Dawson James Securities

Ratings Action: INITIATE
Current Rating: Buy

Additional Comments: Analyst believes that Immune Response can gain additional share valuation in the near-term with the successful progress of REMUNE clinical trials in Europe and additional discussions with the US FDA. The $8-$10 price target for IMNR stock is based on the share price two years ago, before disappointing initial determinations were made by the Spanish data review board.

This rating information was reported by PR Newswire.

JS200

[js200]

VOLUME(+): IMNR Volume 62% > 20-adsv, Stock +12.23%

Thursday , September 04, 2003 14:36 ET

This is the 1st VOLUME alert for IMNR in the past 7 calendar days.

Trading for Immune Response Corporation (NASDAQ NM: IMNR) has been heavier than usual in today`s session. By 14:35 ET, the stock had already traded 391,800 shares via 452 trades. The cumulative volume is 62.41% above its 20-day average of 241,238. Normally the stock experiences around 280 individual trades per session.

So far, today`s volume surge has caused a net rise in IMNR`s stock price. At the time of this alert, the stock was trading at $2.110, up $0.230 (+12.23%).

One year ago, the Company`s shares closed at $2.080. The price has gained more than 1 percent since then.

Over the last 10 trading session IMNR has traded in a range between $1.000 and $2.000 and is currently trading 46.45% below its 52-week high of $3.940 set on June 23, 2003 and 441.03% above its 52-week low of $0.390 from November 21, 2002.

In the previous 3 sessions, IMNR trading has displayed a mixed trend. Closing results have been as follows:

September 03, 2003 --- closed at $1.880 up $0.250 (+15.34%) on 500,000 shares
September 02, 2003 --- closed at $1.630 up $0.040 (+2.52%) on 162,700 shares
August 29, 2003 --- closed at $1.590 down $0.100 (-5.92%) on 89,570 shares

The Company last released news on September 04, 2003 (today):

"Dawson James Securities Initiates Coverage On Immune Response Corp. (IMNR) With A Buy Rating And A 12-Month Price Target Of $8-$10"

IMMUNE RESPONSE CORPORATION
The Immune Response Corporation is a biopharmaceutical company developing immune-based therapies to include T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted, non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection. The Company’s lead product candidate is a patented immune-based therapy for the treatment of HIV called Remune( R).

JS200

[js200]

Last Trade: 2.210 Change: 0.330 (+17.553%)
Previous Close: 1.880 Volume: 575,800
Bid: 2.190 Ask: 2.200
Today`s Open: 1.870 # of Trades: 689


Day High: 2.280 Day Low: 1.840
52 Week High: 3.940 52 week Low: 0.280
Market Cap: 47.13M Avg Daily Vol: 241,238
EPS: -2.77 PE Ratio: -0.798
Dividend: N/A Yield: N/A

JS200

[oski]

Sehr Interressant ,ab Morgen bin ich wieder dabei
Phase 2 kann kommen

[js200]

Last Trade: 2.160 Change: 0.280 (+14.894%)
Previous Close: 1.880 Volume: 772,800
Bid: 2.200 Ask: 2.240
Today`s Open: 1.870 # of Trades: 863


JS200

[oski]

Ask 2.50

[js200]

Internet Stock Review Reports on IMNR

Friday , September 05, 2003 09:06 ET

A recent Internet Stock Review alert noted that a Director of Research for Dawson James Securities, a Division of ViewTrade Financial, has initiated coverage on Immune Response Corporation (Nasdaq SC: IMNR).

IMNR is a biopharmaceutical company.

On 09/04/2003, IMNR closed at $2.16000, *** Immune Response Corporation (Nasdaq SC: IMNR)

The Internet Stock Review is owned by a Public Relations firm (Internet PR Group, Inc).

After going over their Disclosure/Disclaimer statement, Knobias was unable to determine whether or not Internet Stock Review was compensated.


JS200

[js200]

09/05/2003 (14:11 ET) VOLUME(+): IMNRZ Volume 565% > 20-adsv, Stock +6.25% - Knobias
09/05/2003 (10:22 ET) VOLUME(+): IMNR Volume 31% > 20-adsv, Stock +19.91% - Knobias
09/05/2003 (09:06 ET) Internet Stock Review Reports on IMNR - Knobias
09/04/2003 (14:36 ET) VOLUME(+): IMNR Volume 62% > 20-adsv, Stock +12.23% - Knobias
09/04/2003 (14:29 ET) RATING(1): Dawson James Initiates IMNR Rating @ Buy - Knobias


JS200

[oski]

-

[oski]

das Volumen ist sehr Stark da wird bald eine News folgen

[js200]

@OSKI

Dann lassen wir die NEWS anmarschieren

JS200

[js200]

Thursday , August 28, 2003 03:06 ET

CARLSBAD, Calif., Aug 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced that due to the Labor Day holiday and procedural delays in processing sales of its Class A Warrants, the Company has extended the redemption date for its Class A Warrants from Wednesday September 3, 2003 to Monday, September 8, 2003. Holders of Class A Warrants may avoid the redemption of their Class A Warrants by paying the exercise price for their warrants to the Company`s warrant agent, Computershare Trust Company, Inc., prior to 5:00 P.M. Eastern Standard Time on Friday, September 5, 2003, the last business day before the redemption date. Furthermore, the Company has granted a "broker-protect" period through Friday, September 26, 2003 to allow for the processing of paperwork in connection with the exercise of the Class A Warrants; holders of Class A Warrants who deliver funds for their exercise by the September 5, 2003 deadline must deliver their warrants for settlement on or before the "broker-protect" period ends.

JS200

[js200]

Vom Freitag

IMNR
IMMUNE RESPONSE CORP
2.360
+0.200 +9.26%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 9/5/2003 (0) days ago, when the stock price was 2.360. Since then the stock gained 0.00% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 2.360
Previous Close 2.160
Change +0.200
% Change +9.26%
Volume 1,169,398
Stock Activity
Open 2.270
Day`s High 2.900
Day`s Low 2.210
52 Week High 3.750
52 Week Low 0.590

Stock Price History
3 Month % Change 11.85
6 Month % Change 80.15
12 Month % Change 13.57
Stock Statistics
50 Day Close MA 2.201
200 Day Close MA 1.644
65 Day Volume MA 246,441

JS200

[js200]

Morgen fällt die Entscheidung

http://www.investtech.com/nasdaq/ana/imnr.htm

JS200

[js200]

Noch nichts Neues, alles beim Alten

09/05/2003 (14:11 ET) VOLUME(+): IMNRZ Volume 565% > 20-adsv, Stock +6.25% - Knobias
09/05/2003 (10:22 ET) VOLUME(+): IMNR Volume 31% > 20-adsv, Stock +19.91% - Knobias
09/05/2003 (09:06 ET) Internet Stock Review Reports on IMNR - Knobias
09/04/2003 (14:36 ET) VOLUME(+): IMNR Volume 62% > 20-adsv, Stock +12.23% - Knobias
09/04/2003 (14:29 ET) RATING(1): Dawson James Initiates IMNR Rating @ Buy


JS200

[Truthforever]

Was für eine Entscheidung soll denn heute fallen?

[js200]

Last Trade: 2.400 Change: 0.040 (+1.695%)
Previous Close: 2.360 Volume: 734,000
Bid: 2.300 Ask: 2.400
Today`s Open: 2.550 # of Trades: 984

JS200

[wolf cub]

Dawson James Securities (IMNR)

5 September 2003, 07:34am ET

IMNR: Initiate Coverage with an Buy - New management team and new advisory board - Immune Response has replaced its management team with a new CEO, CFO and two top R&D managers in an effort to get back on-track with its clinical programs; new advisory board members include leading HIV clinicians and practitioners in the US and Europe.

[js200]

Last Trade: 2.420 Change: 0.020 (+0.833%)
Previous Close: 2.400 Volume: 272,100
Bid: 2.380 Ask: 2.420
Today`s Open: 2.390 # of Trades: 428

Day High: 2.480 Day Low: 2.330
52 Week High: 3.940 52 week Low: 0.280
Market Cap: 78.11M Avg Daily Vol: 348,108
EPS: -2.77 PE Ratio: -0.874
Dividend: N/A Yield: N/A

JS200

[oski]

Pfeizer wird sich die Augen reiben wenn IMNR das lang ersehnte Produkt auf dem Markt bringt Kursziel 50$

[js200]

@OSKI

Trotzdem Vorsicht

http://www.investtech.com/nasdaq/ana/imnr.htm

JS200

[js200]

The Immune Response Corporation Receives Approximately $3.2 Million in Gross Proceeds Through the Exercise of Class A Warrants

Wednesday, September 10, 2003 08:30 ET

CARLSBAD, Calif., Sep 10, 2003 /PRNewswire-FirstCall via COMTEX/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received gross proceeds of approximately $3.2 million through the exercise of about 2.4 million Class A warrants in connection with the redemption of the warrants. The exercise of the warrants completes the first phase of the Company`s plan to strengthen its financial position, which has improved with the receipt of more than $13 million in cash plus approximately $2.4 million debt reduction since March of this year. The next phase of the plan is expected to involve the exercise of the Company`s Class B warrants. If all of the outstanding Class B warrants are exercised, the Company would receive gross proceeds of about $17 million.

"We are pleased to have made such considerable progress toward financial stability over the past several months," said John N. Bonfiglio, Ph.D., Chief Executive Officer of The Immune Response Corporation. "In addition to raising cash and lowering our debt, we have appreciably reduced the administrative component of the burn rate, eliminated underutilized assets, and stopped internal work on projects unrelated to our lead product candidate.

"We are now in a much improved position to focus on the continuing clinical development of REMUNE(R), a novel vaccine candidate for the treatment of HIV and AIDS," Dr. Bonfiglio stated. "REMUNE is currently being evaluated in a Phase II clinical study in Spain, and we intend to initiate an additional Phase II study in the fall of this year."

The Company issued the Class A warrants in its December 10, 2002 private placement. Holders of Class A warrants whose warrants were exercised received one share of Common Stock and one Class B warrant which is exercisable for one share of Common Stock at an initial exercise price of $1.77. Holders of Class A warrants whose warrants were redeemed will receive $0.01 per Class A warrant.

About The Immune Response Corporation and REMUNE(R)

The Immune Response Corporation is a biopharmaceutical company dedicated to treating and preventing HIV and AIDS through the development of immune- based therapeutic vaccines such as REMUME, its lead product candidate. The Company was co-founded by medical pioneer Dr. Jonas Salk, who was instrumental in the formulation of REMUNE, which is currently in Phase II clinical development.

HIV, the human immunodeficiency virus, is the virus that causes AIDS, a condition that slowly destroys the body`s immune system, making it vulnerable to infections. REMUNE is designed to induce a specific immune response to the HIV virus. It is comprised of HIV-1 virus that has been chemically killed and inactivated so that it is non-infectious, plus an adjuvant that helps enhance the body`s immune response to the virus. More than 60 million people have been infected with HIV since it was first recognized in 1981, and approximately 40 million people around the world are living with HIV today.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether holders will exercise their Class B warrants, whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE, the uncertainty of successful completion of any such clinical trials, whether REMUNE will be effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE in preclinical trials. These risks, among others, are set forth in The Immune Response Corporation`s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2002, and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


REMUNE(R) is a registered trademark of The Immune Response Corporation.

For further information, please contact:
Investors: Kathy Lane, phone [phone] or [e-mail]
Media: Gwen Rosenberg, phone [phone] or cell [phone]


SOURCE The Immune Response Corporation


CONTACT: Investors, Kathy Lane, [phone], [e-mail], or
Media, Gwen Rosenberg, [phone], or cell, [phone], both of The
Immune Response Corporation

URL: http://www.imnr.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: California
INDUSTRY KEYWORD: MTC
BIO
HEA
OTC
SUBJECT CODE: OTC


STOCK SYMBOLS: [(imnr)]


JS200

[js200]

09/10/2003 (08:30 ET) The Immune Response Corporation Receives Approximately $3.2 Million in Gross Proceeds Through the Exercise of Class A Warrants - PR Newswire
09/08/2003 (14:37 ET) BTC: Biotechs Keep Momentum in Late-day Trading - Knobias
09/08/2003 (13:16 ET) VOLUME(+): IMNR Volume 47% > 20-adsv, Stock +5.93% - Knobias
09/08/2003 (09:58 ET) 52W HIGH: New 52-Wk High for IMNRZ @ $1.330 up47.78% - Knobias
09/05/2003 (14:11 ET) VOLUME(+): IMNRZ Volume 565% > 20-adsv, Stock +6.25% - Knobias


JS200

[obolus]

Hört sich doch gut an!

Gibt es schon vorbörsliche Kurse bzw. Reaktionen auf diese News?

[fonx]

Was ist los????????????????????????FONX

[fonx]

Was ist denn los? Etwa Gewinnmitnahmen? Oder wissen einige einiges mehr? FONX

[js200]

@FONX

Die Gewinnmitnahmen laufen, war vor der NEWS zu hoch gelaufen

JS200

[js200]

RATING(=): Taglich Bro Reiterates IMNR Rating @ Neutral

Thursday , September 11, 2003 13:18 ET

Issuer: Immune Response Corporation (NasdaqSC: IMNR)
Analyst Firm: Taglich Brothers Inc.

Ratings Action: REITERATION
Current Rating: Neutral

Additional Comments: Taglich is maintaining coverage of The Immune Response Corporation (IMNR) with a Neutral rating and no price target, pending further clinical, business, and financing developments. The particular developments that it is watching for include: 1) Further progress of REMUNE through the clinical and regulatory processes; 2) Results of the Italian phase II trial scheduled to commence in the third quarter of 2003; 3) The Company’s deployment of cash received from recent financings; and 4) A change in the auditor’s opinion related to the Company’s ability to continue as a going concern.

This rating information was reported by Taglich Brothers Inc..


JS200

[js200]

The Immune Response Corporation Continues to Expand Its HIV/AIDS Expertise With the Appointment of Peter L. Salk, M.D., to Its Scientific Advisory Board
via COMTEX

September 17, 2003

CARLSBAD, Calif., Sep 17, 2003 /PRNewswire-FirstCall via COMTEX/ --

The Immune Response Corporation (Nasdaq: IMNR) today announced the appointment of Peter L. Salk, M.D., to its Scientific Advisory Board as part of the company`s continuing expansion of its HIV/AIDS expertise. The Scientific Advisory Board was established recently to provide guidance for the renewed clinical development of REMUNE(R), a novel vaccine candidate for the treatment of HIV and AIDS. Dr. Salk, who is the son of Dr. Jonas Salk, the Company`s co-founder and the primary force behind the initial development of REMUNE, is himself an internationally respected authority on HIV/AIDS prevention and treatment, and is currently Vice President and Scientific Director of the Jonas Salk Foundation.

`The addition of Dr. Salk to our Scientific Advisory Board is especially valuable at this critical and exciting time for Immune Response,`said John N. Bonfiglio, Ph.D., Chief Executive Officer of the company. `In the past few months, we have re-dedicated Immune Response to its founding purpose -- the treatment and prevention of HIV disease through the development of vaccines and immune-based therapies. We have brought in new management, reduced expenses, secured additional funding, initiated a new clinical study in Spain in June, and are preparing to start a second new clinical study in Europe this fall.

`An important aspect of our activities has been the establishment of a Scientific Advisory Board composed of physicians who are on the forefront of HIV/AIDS research and therapy,`Dr. Bonfiglio noted. `It`s very timely for Dr. Peter Salk, a renowned physician-researcher, to be joining us as we move forward with the revitalized clinical development of REMUNE. Peter has already provided some of the key insights into the research behind this vaccine candidate. We are privileged to have him help us strive to fulfill the promise of the technology identified by his father.`

`I welcome the opportunity to work with Immune Response and play a role in the direction of its clinical and scientific programs,`Dr. Salk said. `I have spent many years conducting research in the areas of vaccine development, immunotherapy, autoimmune disease, and cancer biology. I`m looking forward to participating in the continuing development of REMUNE and collaborating with the distinguished members of The Immune Response Scientific Advisory Board.`

Dr. Salk graduated Phi Beta Kappa from Harvard University and Alpha Omega Alpha from Johns Hopkins University School of Medicine. He has authored numerous scientific papers and is actively engaged in the introduction of treatment regimens for HIV infection in Africa and China.

Other members of company`s Scientific Advisory Board include the Chairman, Gilbert S. Omenn, M.D., Ph.D., Professor of Internal Medicine, Human Genetics and Public Health, University of Michigan; Mario Salvatore Clerici, M.D., Chair of Immunology, University of Milan; Brian G. Gazzard, M.A., M.D., F.R.C.P., Professor, Chelsea &Westminster Hospital in London; and Eduardo Fernandez-Cruz, M.D., Professor and Head of the Department of Immunology, University General Hospital Gregorio Maranon in Madrid and principal investigator of the Phase II clinical trial of REMUNE (STIR-2102) conducted previously in Spain and the follow-up study (REMIT-2102) presently underway.

About The Immune Response Corporation and REMUNE(R)

The Immune Response Corporation is a biopharmaceutical company dedicated to treating and preventing HIV and AIDS through the development of immune-based therapeutic vaccines such as REMUNE, its lead product candidate. The Company was co-founded by medical pioneer Dr. Jonas Salk, who was instrumental in the formulation of REMUNE, which is currently in Phase II clinical development.

HIV, the human immunodeficiency virus, is the virus that causes AIDS, a condition that slowly destroys the body`s immune system, making it vulnerable to infections. REMUNE is designed to induce a specific immune response to the HIV virus. It is comprised of HIV-1 virus that has been chemically killed and inactivated so that it is non-infectious, plus an adjuvant that helps enhance the body`s immune response to the virus. More than 60 million people have been infected with HIV since it was first recognized in 1981, and approximately 40 million people around the world are living with HIV today.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE, the uncertainty of successful completion of any such clinical trials, whether REMUNE will be effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE in preclinical trials. These risks, among others, are set forth in The Immune Response Corporation`s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2002, and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation. For further information please contact: The Immune Response Corporation (Investors) - Kathy Lane, [phone] or [e-mail] (Media) - Gwen Rosenberg, [phone]
SOURCE The Immune Response Corporation

investors, Kathy Lane, [phone], [e-mail] , or media, Gwen Rosenberg, [phone], both of The Immune Response Corporation (IMNR)

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

The Immune Response Corporation Licenses Hybridon`s 2nd-Generation CpG DNA Adjuvant, AMPLIVAX(TM), for Use in Development of a Novel Vaccine for the Prevention and Treatment of HIV
via COMTEX

October 9, 2003

CARLSBAD, Calif. and CAMBRIDGE, Mass., Oct 9, 2003 /PRNewswire-FirstCall via COMTEX/ --

The Immune Response Corporation (Nasdaq: IMNR) and Hybridon, Inc. (OTC Bulletin Board: HYBN) today announced that they have entered into a license agreement for the use of AMPLIVAX(TM) as an adjuvant in the development of a novel vaccine candidate for the prevention and treatment of HIV, the virus that causes AIDS. The new vaccine candidate, which has already demonstrated activity in laboratory experiments, combines the whole-killed vaccine technology employed in REMUNE(R), an immune-based HIV therapeutic vaccine being evaluated in Phase II clinical trials by The Immune Response Corporation, plus AMPLIVAX, Hybridon`s 2nd generation immunomodulatory oligonucleotide (IMO(TM)) adjuvant designed to enhance the immune response to a vaccine antigen. The Immune Response Corporation separately will continue its clinical development of REMUNE as a potential treatment for patients already infected with the HIV virus.

`As The Immune Response Corporation presses forward with the clinical development of REMUNE, we intend to expand our efforts in the HIV area by beginning development of the new vaccine candidate for broader prophylactic and therapeutic applications,`said John Bonfiglio, Ph.D., CEO of The Immune Response Corporation. `In preclinical data generated to date, the use of REMUNE plus AMPLIVAX has elicited a significantly enhanced HIV-1 specific T-cell response, indicating the potential for the combined agents to function as a novel HIV vaccine. We are currently completing a number of preclinical studies and plan to move this project into clinical development quickly. The fact that REMUNE has a history of being evaluated in human trials and that AMPLIVAX has been studied in humans for other uses should facilitate the clinical development of the combined product candidate.`

`We are very pleased to work with The Immune Response Corporation on the development of a novel HIV vaccine candidate using our AMPLIVAX adjuvant,` added Stephen R. Seiler, CEO of Hybridon, Inc. `AMPLIVAX has shown encouraging pre-clinical results as an adjuvant with a broad range of vaccines targeted to multiple disease indications.`

AMPLIVAX is presently known as HYB2055. HYB2055 is currently in two Phase I clinical trials. Adjuvant applications of HYB2055 will be referred to as AMPLIVAX.

About The Immune Response Corporation and REMUNE(R)

The Immune Response Corporation is a biopharmaceutical company dedicated to treating and preventing HIV and AIDS through the development of immune-based therapeutic vaccines such as REMUNE, its lead product candidate. The Company was co-founded by medical pioneer Dr. Jonas Salk, who was instrumental in the formulation of REMUNE, which is currently in Phase II clinical development.

HIV, the human immunodeficiency virus, is the virus that causes AIDS, a condition that slowly destroys the body`s immune system, making it vulnerable to infections. REMUNE is designed to induce a specific immune response to the HIV virus. It is comprised of HIV-1 virus that has been chemically killed and inactivated so that it is non-infectious, plus an adjuvant that helps enhance the body`s immune response to the virus. More than 60 million people have been infected with HIV since it was first recognized in 1981, and approximately 40 million people around the world are living with HIV today.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the new vaccine candidate will be effective for the prevention or treatment of HIV or whether it will enter into clinical trials, whether The Immune Response Corporation will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE, the uncertainty of successful completion of any such clinical trials, whether REMUNE will be effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE in preclinical trials. These risks, among others, are set forth in The Immune Response Corporation`s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2002, and subsequent Quarterly Reports on Form 10-Q. The Immune Response Corporation undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation.

About Hybridon

Hybridon, Inc. is a leader in the discovery and development of novel therapeutics and diagnostics, based on synthetic DNA. The Company now has four technology platforms: 1) Synthetic immunomodulatory oligonucleotide (IMO(TM)) motifs that act to modulate responses of the immune system; 2) Antisense technology which uses synthetic DNA to block the production of disease-causing proteins at the cellular level; 3) Synthetic DNA drug candidates that enhance the antitumor activity of certain marketed anticancer drugs, thereby increasing their effectiveness; and 4) novel synthetic DNA structures for identifying gene function, which can be used for target validation and drug discovery as well as for PCR-based gene amplification.

This press release contains forward-looking statements concerning Hybridon that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, `believes,``anticipates,``plans,``expects,``estimates,``intends,` `should,``could,``will,``may,`and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Hybridon`s actual results to differ materially from those indicated by such forward-looking statements including risks as to whether results obtained in preclinical studies or early clinical trials will be indicative of results obtained in future preclinical studies or clinical trials, or warrant further clinical trials and product development; whether products based on Hybridon`s technology will advance through the clinical trial process and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if such products receive approval, they will be successfully distributed and marketed; whether the patent and patent applications owned or licensed by Hybridon will protect the company`s technology and prevent others from infringing it; whether Hybridon`s cash resources will be sufficient to fund product development and such other important factors as are set forth under the caption `Risk Factors`in Hybridon`s Quarterly Report on Form 10-Q for the quarter ended June 30, 2003, which important factors are incorporated herein by reference. Hybridon disclaims any intention or obligation to update any forward-looking statements.

Hybridon`s IMO Technology

Hybridon`s IMO(TM) technology comprises a portfolio of compounds that mimic bacterial DNA that activate the human immune system to fight diseases. Independent reports have shown that CpG oligonucleotides are useful in the treatment of cancer, infectious diseases and asthma/allergies, either alone or in combination with antigens, antibodies or conventional therapies.

AMPLIVAX and IMO are trademarks of Hybridon, Inc. For further information please contact: The Immune Response Corporation (Investors) - Kathy Lane, [phone] or [e-mail] (Media) - Gwen Rosenberg, Rosenberg Business Communications, [phone] Hybridon, Inc. (Investors) - Robert G. Andersen, [phone], ext. 5517 or [e-mail] (Media) Robert Stanislaro, Noonan Russo Presence, [phone]
SOURCE The Immune Response Corporation; Hybridon, Inc.

investors, Kathy Lane of The Immune Response Corporation,[phone], [e-mail] ; or media, Gwen Rosenberg of RosenbergBusiness Communications, [phone], for The Immune Response Corporation;or investors, Robert G. Andersen of Hybridon, Inc., [phone], ext.5517, [e-mail] ; or media, Robert Stanislaro of Noonan RussoPresence, [phone], for Hybridon, Inc.(IMNR HYBN)
Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[js200]

10/09/2003 (10:07 ET) VOLUME(-): IMNR Volume 16% > 20-adsv, Stock -3.27% - Knobias
10/09/2003 (08:37 ET) IMNR and HYBN Sign Lisence Agreement for HIV Vaccine - Knobias
10/09/2003 (08:30 ET) The Immune Response Corporation Licenses Hybridon`s 2nd-Generation CpG DNA Adjuvant, AMPLIVAX(TM), for Use in Development of a Novel Vaccine for the Prevention and Treatment of HIV - PR Newswire
10/08/2003 (16:22 ET) CLOSER(+): Last 90 Min, IMNR Jumps +9.37%; Vol +295% - Knobias
10/07/2003 (07:50 ET) HCR: Smith Barney Highlights the Healthcare Sector - Knobias

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


10/14/2003 (12:25 ET) StreetInsider Alert for IMNR - StreetInsider



10/14/2003 (10:26 ET) VOLUME(-): IMNR Volume 14% > 20-adsv, Stock -11.24% - Knobias



10/14/2003 (09:54 ET) Capital Research Group Announces Investment Opinion: Pondering the Fed! - Internet Wire



10/14/2003 (08:40 ET) StreetInsider Alert for IMNR - StreetInsider



10/14/2003 (08:31 ET) The Immune Response Corporation Enters into Agreements for $12.0 Million Private Placement Financing - PR Newswire



10/13/2003 (11:11 ET) VOLUME(+): IMNR Volume 11% > 20-adsv, Stock +1.08% - Knobias



10/13/2003 (08:01 ET) Capital Research Group Announces Investment Opinion: The Fed in the Foreseeable Future! - Internet Wire



10/10/2003 (13:35 ET) StreetInsider Alert for IMNR - StreetInsider



10/10/2003 (11:16 ET) TIRC licenses Hybridon`s Amplivax as an adjuvant vaccine candidate - Datamonitor



10/10/2003 (10:11 ET) Stocks Opening Significantly Higher/Lower Than Close - Knobias



10/10/2003 (09:51 ET) VOLUME(+): IMNRZ Volume 2151% > 20-adsv, Stock +17.14% - Knobias



10/10/2003 (09:46 ET) VOLUME(+): IMNR Volume 280% > 20-adsv, Stock +18.00% - Knobias



10/10/2003 (08:47 ET) IMNR Seeking Partner For HIV Drug Says BusinessWeek - Knobias



10/10/2003 (08:45 ET) StreetInsider Alert for IMNR - StreetInsider



10/10/2003 (07:49 ET) RATING(=): Dawson James Keeps IMNR Rating @ Buy; Sets Tgt @ $8; Analyst Notes - Knobias



10/10/2003 (06:15 ET) BusinessWeek Reports on IMNR - Knobias



10/09/2003 (10:07 ET) VOLUME(-): IMNR Volume 16% > 20-adsv, Stock -3.27% - Knobias



10/09/2003 (08:37 ET) IMNR and HYBN Sign Lisence Agreement for HIV Vaccine - Knobias



10/09/2003 (08:30 ET) The Immune Response Corporation Licenses Hybridon`s 2nd-Generation CpG DNA Adjuvant, AMPLIVAX(TM), for Use in Development of a Novel Vaccine for the Prevention and Treatment of HIV - PR Newswire



10/08/2003 (16:22 ET) CLOSER(+): Last 90 Min, IMNR Jumps +9.37%; Vol +295% - Knobias



10/07/2003 (07:50 ET) HCR: Smith Barney Highlights the Healthcare Sector - Knobias



10/06/2003 (16:57 ET) Mkt Wrap: MOT & RMBS Up Big; SOX Flat; Biotechs Down - Knobias



10/06/2003 (15:16 ET) Profit Taking Hits Equities in Late Trading - Knobias



10/02/2003 (12:30 ET) Software Sector Takes Nasdaq to Lows of the Day - Knobias



10/01/2003 (07:34 ET) BTC: Smith Barney Previews Q3 Earnings for Biotechs - Knobias

JS200